Negative drug results cost AbbVie billions of dollars in market value and convinced analysts that Bristol Myers had placed a ...

Shares in AbbVie slumped Monday after the company disclosed its psychiatric medicine emraclidine didn’t best placebo in two ...

The Food and Drug Administration has cleared Novavax to move forward with testing of a combination vaccine for COVID-19 and ...

Developer Autolus set a list price of $525,000 for its new cell therapy, which it will sell for a type of leukemia under the ...

“As the industry transitions from traditional drug discovery and life sciences R&D to faster-paced, complex modalities, ...

The company’s first product, the SuperMethyl™ - Fast Bisulfite Conversion Kit was launched at the Chicago Biomedical Consortium ’s 2024 Chicago BioCapital Summit. This advanced kit achieves over 99.5% ...

After Kalaris and AlloVir combine, the new company will have about $100 million to advance a treatment for age-related ...

AstraZeneca and Amgen's drug could have a new use after positive Phase 3 study results. Elsewhere, Jazz set new plans for a ...

Past comments by Robert F. Kennedy Jr. hint at the ideas he might advocate for if given a role in the incoming Trump ...

On the heels of its most advanced medicine flunking a key study, the drugmaker is looking at the different paths it could ...

Sales of Moderna’s COVID-19 shot exceeded expectations, but the company’s launch of its new RSV vaccine has started slowly.

Elevidys sales have increased since the FDA made a controversial choice to expand the therapy's use. Meanwhile, Sarepta is ...